Bihua Chen
Founder, CEO & Portfolio Manager @ Cormorant Asset Management
Boston, United States
Bihua Chen is a Series A investor at Cormorant Asset Management in Boston focused on Health Care and Biotechnology. Bihua Chen is the Founder, CEO & Portfolio Manager at Cormorant Asset Management.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 69%
Last updated:
For AI agents: llms.txt
Industries Bihua Chen invests in
Stages Bihua Chen invests in
Countries Bihua Chen invests in
Investment Focus
Industry
- Health Care 12 (34%)
- Biotechnology 12 (34%)
- Medical 9 (26%)
- Therapeutics 9 (26%)
- Medical Device 6 (17%)
Stage
- Series A 10 (29%)
- Series B 10 (29%)
- Series C 5 (14%)
- Series E 2 (6%)
- Post-IPO Equity 2 (6%)
Country
- United States 17 (49%)
- Switzerland 2 (6%)
- France 1 (3%)
- United Kingdom 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BlossomHill Therapeutics
|
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. | $84M / Series B / Dec 10, 2025 | |
Ensoma
|
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. | $53M / Sep 22, 2025 | |
BBOT
|
BridgeBio Oncology Therapeutics operates as a biopharmaceutical company. | $261M / Post-IPO Equity / Aug 11, 2025 | |
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $120M / Series E / Mar 26, 2025 | |
Numab
|
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics. | $54.8M / Series C / Jan 09, 2025 | |
Adona Medical
|
Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options andenable providers to improve care for heart failure patients. | $33.5M / Series C / Jul 10, 2024 | |
Averto Medical
|
Savage Medical manufactures devices for medical use, enabling patients to get solutions for gastrointestinal diseases. They offer solutions for patients suffering from gastrointestinal diseases. | $30M / Series A / May 07, 2024 | |
|
BlossomHill Therapeutics
|
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. | $100M / Series B / Jan 02, 2024 | |
|
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $40M / Series D / Nov 21, 2023 | |
Akura Medical
|
Akura Medical offers products and services centered on mechanical thrombectomy and imaging software for venous thromboembolism treatment. Its Katana Thrombectomy System uses a steerable catheter with integrated jet-based technology to access clot material, break it down, and support clot removal during a procedure. The system provides proceduralfeedback intended to help clinicians assess clot engagement and clearance while operating the device. Akura Medical also develops NavIQ, a software tool that transforms CT angiograms into 3D vascular models that display clot location and morphology to guide procedural planning. Together, these products form a workflow that supports physicians from pre-procedure assessment through clot extraction in cases involving pulmonary embolism and related VTE conditions. | $35M / Series B / Oct 03, 2023 | |
| See all 35 investments → | |||
Co-Investors
About Cormorant Asset Management
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Cormorant Asset Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bihua Chen
Founder, CEO & Portfolio Manager
|
|||
|
Edward Jay Scollins
CFO and COO
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bihua Chen invest in?
Bihua Chen invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 35 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Bihua Chen last invest?
The most recent investment recorded for Bihua Chen closed in Dec 2025. Shizune tracks 35 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
